Drug Insight: aggrecanases as therapeutic targets for osteoarthritis (original) (raw)

• Glasson SS et al. (2005) Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434: 644–648
  Article CAS Google Scholar
• Stanton H et al. (2005) ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434: 648–652
  Article CAS Google Scholar
• Fosang AJ et al. (2008) ADAMTS-5: the story so far. Eur Cell Mater 15: 11–26
  Article CAS Google Scholar
• Tortorella MD and Malfait AM (2008) Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. Curr Pharm Biotechnol 9: 16–23
  Article CAS Google Scholar
• Bondeson J et al. (2006) The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 8: R187
  Article Google Scholar
• Struglics A et al. (2006) Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 14: 101–113
  Article CAS Google Scholar
• Fosang AJ et al. (1996) Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 98: 2292–2299
  Article CAS Google Scholar
• Lark MW et al. (1997) Aggrecan degradation in human cartilage. Evidence for both metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 100: 93–106
  Article CAS Google Scholar
• van Meurs JB et al. (1999) Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum 42: 1128–1139
  Article CAS Google Scholar
• Maehara H et al. (2007) G1-G2 aggrecan product that can be generated by M-calpain on truncation at Ala709-Ala710 is present abundantly in human articular cartilage. J Biochem (Tokyo) 141: 469–477
  Article CAS Google Scholar
• Little CB et al. (2007) Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J Clin Invest 117: 1627–1636
  Article CAS Google Scholar
• East CJ et al. (2007) ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulphate-rich region of aggrecan. J Biol Chem 282: 8632–8640
  Article CAS Google Scholar
• Glasson SS et al. (2004) Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 50: 2547–2558
  Article CAS Google Scholar
• Behera AK et al. (2006) Role of aggrecanase 1 in Lyme arthritis. Arthritis Rheum 54: 3319–3329
  Article CAS Google Scholar
• Rogerson FM et al. (2008) Identification of a novel aggrecan-degrading activity in cartilage: studies of mice deficient in both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 58: 1664–1673
  Article CAS Google Scholar
• Appleton CT et al. (2007) Global analyses of gene expression in early experimental osteoarthritis. Arthritis Rheum 56: 1854–1868
  Article CAS Google Scholar
• Pelletier JP et al. (2005) The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases. Arthritis Res Ther 7: R1091–R1102
  Article CAS Google Scholar
• Little CB et al. (2006) Regional changes in expression and activity of ADAMTS and MMP enzymes in cartilage in an ovine model of early osteoarthritis. Trans Orthop Res Soc 31: 1461
  Google Scholar
• Bau B et al. (2002) Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 46: 2648–2657
  Article CAS Google Scholar
• Plaas A et al. (2007) Aggrecanolysis in human osteoarthritis: confocal localization and biochemical characterization of ADAMTS5-hyaluronan complexes in articular cartilages. Osteoarthritis Cartilage 15: 719–734
  Article CAS Google Scholar
• Malfait A-M et al. (2002) Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 277: 22201–22208
  Article CAS Google Scholar
• Naito S et al. (2007) Expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic cartilage. Pathol Int 57: 703–711
  Article CAS Google Scholar
• Roach HI et al. (2005) Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthritis Rheum 52: 3110–3124
  Article CAS Google Scholar
• Bastow ER et al. (2008) Hyaluronan synthesis and degradation in cartilage and bone. Cell Mol Life Sci 65: 395–413
  Article CAS Google Scholar
• Song RH et al. (2007) Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 56: 575–585
  Article CAS Google Scholar
• Abbaszade I et al. (1999) Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 274: 23443–23450
  Article CAS Google Scholar
• Tortorella MD et al. (1999) Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 284: 1664–1666
  Article CAS Google Scholar
• Cooper C et al. (2000) Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum 43: 995–1000
  Article CAS Google Scholar
• Massardo L et al. (1989) Osteoarthritis of the knee joint: an eight year prospective study. Ann Rheum Dis 48: 893–897
  Article CAS Google Scholar
• Spector TD et al. (1992) Radiological progression of osteoarthritis: an 11 year follow up study of the knee. Ann Rheum Dis 51: 1107–1110
  Article CAS Google Scholar
• Majumdar MK et al. (2007) Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis. Arthritis Rheum 56: 3670–3674
  Article CAS Google Scholar
• Ilic MZ et al. (2007) Distinguishing aggrecan loss from aggrecan proteolysis in ADAMTS-4 and ADAMTS-5 single and double deficient mice. J Biol Chem 282: 37420–37428
  Article CAS Google Scholar
• Vlad SC et al. (2007) Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 56: 2267–2277
  Article CAS Google Scholar
• Reginster JY (2007) The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 56: 2105–2110
  Article CAS Google Scholar
• Clegg DO et al. (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354: 795–808
  Article CAS Google Scholar
• Herrero-Beaumont G et al. (2007) Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 56: 555–567
  Article CAS Google Scholar
• Zhang W et al. (2007) OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 15: 981–1000
  Article CAS Google Scholar
• Sandy JD et al. (1998) Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 335: 59–66
  Article CAS Google Scholar
• Chan PS et al. (2006) Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. J Rheumatol 33: 1329–1340
  CAS PubMed Google Scholar
• Piepoli T et al. (2005) Glucosamine sulfate inhibits IL-1-stimulated gene expression at concentrations found in humans after oral intake. Arthritis Rheum 52 (Suppl 9): S502
  Google Scholar
• Chan PS et al. (2007) Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. Am J Vet Res 68: 709–715
  Article CAS Google Scholar
• Persiani S et al. (2007) Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 15: 764–772
  Article CAS Google Scholar
• Ghosh P (1999) The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum 28: 211–267
  Article CAS Google Scholar
• Takizawa M et al. (2000) Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. Arthritis Rheum 43: 812–820
  Article CAS Google Scholar
• Munteanu SE et al. (2000) Calcium pentosan polysulfate inhibits the catabolism of aggrecan in articular cartilage explant cultures. Arthritis Rheum 43: 2211–2218
  Article CAS Google Scholar
• Altman RD (1999) Calcium pentosan in a canine model of osteoarthritis. Osteoarthritis Cartilage 7 (Suppl A): 72
  Google Scholar
• Ghosh P et al. (2005) Evaluation of the symptom-modifying effects of pentosan polysulfate in patients with knee osteoarthritis. Results of a randomized placebo-controlled double-blind study. Curr Ther Res 66: 552–571
  Article CAS Google Scholar
• Rintelen B et al. (2006) A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med 166: 1899–1906
  Article CAS Google Scholar
• Fidelix TS et al. (2006) Diacerein for osteoarthritis. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005117. 10.1002/14651858.CD005117.pub2
  Google Scholar
• Smith GNJ et al. (1999) Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum 42: 545–554
  Article CAS Google Scholar
• Tamura T et al. (2001) Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. Osteoarthritis Cartilage 9: 257–263
  Article CAS Google Scholar
• Tamura T and Ohmori K (2001) Rhein, an active metabolite of diacerein, suppresses the interleukin-1alpha-induced proteoglycan degradation in cultured rabbit articular chondrocytes. Jpn J Pharmacol 85: 101–104
  Article CAS Google Scholar
• Legendre F et al. (2007) Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. Clin Exp Rheumatol 25: 546–555
  CAS PubMed Google Scholar
• Mendes AF et al. (2002) Diacerhein and rhein prevent interleukin-1beta-induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-alpha. Pharmacol Toxicol 91: 22–28
  Article CAS Google Scholar
• Little CB et al. (2002) Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage. Arthritis Rheum 46: 124–129
  Article CAS Google Scholar
• Yoo SA et al. (2007) Calcineurin modulates the catabolic and anabolic activity of chondrocytes and participates in the progression of experimental osteoarthritis. Arthritis Rheum 56: 2299–2311
  Article CAS Google Scholar
• Henry ML et al. (1995) A clinical trial of cyclosporine G in cadaveric renal transplantation. Pediatr Nephrol 9 (Suppl): S49–S51
  Article Google Scholar
• Roach HI and Aigner T (2007) DNA methylation in osteoarthritic chondrocytes: a new molecular target. Osteoarthritis Cartilage 15: 128–137
  Article CAS Google Scholar
• Young DA et al. (2005) Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 7: R503–R512
  Article CAS Google Scholar
• Lin HS et al. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150: 862–872
  Article CAS Google Scholar
• Gendron C et al. (2007) Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem 282: 18294–18306
  Article CAS Google Scholar
• Kashiwagi M et al. (2004) Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol Chem 279: 10109–10119
  Article CAS Google Scholar
• Zeng W et al. (2006) Glycosaminoglycan-binding properties and aggrecanase activities of truncated ADAMTSs: comparative analyses with ADAMTS-5, -9, -16 and -18. Biochim Biophys Acta 1760: 517–524
  Article CAS Google Scholar